Pyrimidine compounds and uses thereof
Abstract
This invention features pyrimidine compounds of formula (I): R t is aryl, or heteroaryl; each of R 2 and R 4 , independently, is halogen, nitro, cyano, isothionitro, SR c , or OR c ; or R 2 and R 4 , taken together, is carbonyl; R 3 is R c , alkenyl, alkynyl, OR c , OC(O)R c , SO 2 R c , S(O)R c , S(O 2 )NR c R d , NR c R d , NR c COR d , NR c C(O)OR d , NR c C(O)NR c R d , NR c SO 2 R d , COR c , C(O)OR c , or C(O)NR c R d ; R 5 is H or alkyl; n is 0, 1, 2, 3, 4, 5, or 6; X is O, S, S(O), S(O 2 ), or NR c ; Y is a covalent bond, CH 2 , C(O), C═N—R c , C═N—OR c , C═N—SR c , O, S, S(O), S(O 2 ), or NR c ; Z is N or CH; one of U and V is N, and the other is CR c ; and W is O, S, S(O), S(O 2 ), NR c , or NC(O)R c ; in which each of R a and R b , independently, is H, alkyl, aryl, heteroaryl; and each of R c and R d , independently, is H, alkyl, aryl, heteroaryl, cyclyl, heterocyclyl, or alkylcarbonyl. The featured compounds inhibit the production of IL-12, IL-23 and IL-27 and are useful for treating disorders associated with IL-12, IL-23 and IL-27 overproduction or misregulation, such as inflammatory and immune disorders,
Claims
exact text as granted — not AI-modified1 - 44 . (canceled)
45 . A method of treating a subject with an IL-10, and/or IL-12 related disorder selected from the group consisting of adjuvant arthritis, inflammatory bowel disease, and Crohn's disease, said method comprising administering to the subject an effective amount of a compound of formula (I):
or a pharmaceutically acceptable salt thereof, wherein
R 1 is
aryl, or heteroaryl;
each of R 2 and R 4 , independently, is R c , halogen, nitro, cyano, isothionitro, SR c , or OR c ; or R 2 and R 4 , taken together, is carbonyl. R 3 is R c , alkenyl, alkynyl, OR c , OC(O)R c , SO 2 R c , S(O)R c , S(O 2 )NR c R d , SR c , NR c R d , NR c COR d , NR c C(O)OR d , NR c C(O)NR c R d , NR c SO 2 R d , COR c , C(O)OR c , or C(O)NR c R d ; R 5 is H or alkyl; n is 0, 1, 2, 3, 4, 5, or 6; X is O, S, S(O), S(O 2 ), or NR c ; Y is a covalent bond, CH 2 , C(O), C═N—R c , C═N—OR c , C═N—SR c , O, S, S(O), S(O 2 ), or NR c ; Z is N or CH; one of U and V is N, and the other is CR c ; and W is O, S, S(O), S(O 2 ), NR c , or NC(O)R c ;
in which each of R a and R b , independently, is H, alkyl, aryl, heteroaryl; and each of R c and R d , independently, is H, alkyl, aryl, heteroaryl, cyclyl, heterocyclyl, or alkylcarbonyl.
46 . The method of claim 45 , wherein R 1 is
47 . The method of claim 46 , wherein U is N and V is CH.
48 . The method of claim 46 , wherein Z is N and W is O.
49 . The method of claim 46 , wherein X is NR c .
50 . The method of claim 49 , wherein R c is H, methyl, ethyl, or acetyl.
51 . The method of claim 46 , wherein Y is O or CH 2 , and n is 0, 1, 2, 3, or 4.
52 . The method of claim 46 , wherein one of R a and R b is
wherein:
B is NR i , O, or S;
B′ is N or CR i ;
R g is H, alkyl, or alkoxyl;
R h is halogen, NO 2 , CN, alkyl, aryl, heteroaryl, OR c , OC(O)R c , SO 2 R c , S(O)R B , S(O 2 )NR c R d , SR c , NR c R d , NR c COR d , NR c C(O)OR d , NR c O(O)NR c R d , NR c SO 2 R d , COR c , C(O)OR c , or C(O)NR c R d ;
R i is H, alkyl, or alkylcarbonyl;
p is 0, 1, or 2; and
q is 0, 1, 2, 3, or 4.
53 . The method of claim 52 , wherein one of R a and R b is
and
the other of R a and R b is H or alkyl.
54 . The method of claim 53 , wherein R g is H, methyl, ethyl, propyl, cyclopropyl, methoxy, or ethoxy; R h is F, Cl, CN, methyl, methoxy, ethoxy, OC(O)CH 3 , OC(O)C 2 H 5 , C(O)OH, C(O)OC 2 H 5 , C(O)NH 2 , NHC(O)CH 3 , or S(O 2 )NH 2 ; R i is H, methyl, ethyl, or acetyl, and q is 0, 1, or 2.
55 . The method of claim 54 , wherein R g is methyl or methoxy; R i is H; and q is 0.
56 . The method of claim 54 , wherein U is N and V is CH.
57 . The method of claim 56 , wherein Z is N and W is O.
58 . The method of claim 57 , wherein X is NR c ; and R c is H, methyl, ethyl, or acetyl.
59 . The method of claim 58 , wherein Y is O or CH 2 ; and n is 0, 1, 2, 3, or 4.
60 . The method of claim 54 , wherein Y is O or CH 2 , and n is 0, 1, 2, 3, or 4.
61 . The method of claim 60 , wherein R 3 is aryl or heteroaryl.
62 . The method of claim 60 , wherein R 3 is pyridinyl.
63 . The method of claim 45 , wherein R 1 is aryl or heteroaryl.
64 . The method of claim 45 , wherein the compound is selected from the group consisting of:
or a pharmaceutically acceptable salt thereof.Join the waitlist — get patent alerts
Track US2011288081A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.